At SignaGen Laboratories, we provide high-titer, research-grade recombinant AAV (rAAV) vectors optimized for robust gene overexpression and precise AAV-mediated homology-directed repair (HDR). Our integrated workflow covers vector design, plasmid verification, scalable production, purification, and rigorous quality control to ensure high purity, genome integrity, and reproducible titers for both in vitro and in vivo studies.

For gene overexpression, AAV enables stable, long-term transgene expression in dividing and non-dividing cells with minimal cytotoxicity. For HDR applications, AAV functions as an efficient donor DNA delivery vehicle when paired with programmable nucleases such as CRISPR/Cas systems, supporting accurate genome modification.

AAV is particularly well suited for HDR because its single-stranded DNA genome closely resembles a natural repair template, enhancing homologous recombination efficiency. It provides efficient nuclear delivery of donor sequences, transduces a broad range of cell types, and maintains a strong safety profile with low immunogenicity. Importantly, AAV delivers HDR templates without random genomic integration, reducing off-target risks. Together with available serotypes for tissue-specific targeting, these properties make AAV an ideal vector for precise gene correction and knock-in applications.